Skip to content
Home » News » Health » CDC approves new RSV injection for infants

CDC approves new RSV injection for infants

  • / Updated:
  • Staff Report 

The Centers for Disease Control (CDC) has approved a new shot called ‘nirsevimab’ to prevent respiratory syncytial virus (RSV) in infants under 8 months, marking a significant advancement in combating the most common cause of bronchiolitis and pneumonia in young children in the U.S.

Unlike an immunization that triggers the body to produce antibodies, this treatment is an injection of antibodies.

Designed to last for five to six months, it can effectively cover children throughout the cold season.

Doctors call the shot as a “huge breakthrough,” estimating its cost at $500 per shot but emphasizing its cost-effectiveness compared to hospital treatment for RSV.